The latest research reveals that there are microbes that actually live within cancerous tumors, challenging accepted dogma.

Fundamental to the practice of medicine is to base our decision making on sound scientific research. As such, it is beyond challenging to me, for so many reasons, that one …

(NaturalHealth365) Fraudulent images were used to support findings of key Alzheimer's study, misleading researchers for years.

(NaturalHealth365) Over 5.8 million Americans have Alzheimer's disease. Anthocyanins in blueberries may help support cognition.

We need to reframe our overzealous interventions to eradicate every last molecule of beta-amyloid because it may very well be doing us some good.

Shop Discount vitamins & supplements, natural health products, organic foods and more at best prices. Money back guarantee! Shop online or call 1-800-824-4491.

All magnesium supplements are not the same. Discover here the best magnesium supplement to help improve memory.

Alzheimer's disease continues to be a leading cause of death in the U.S., with 1 in 3 seniors ...

(NaturalHealth365) Alzheimer's disease is the 6th leading cause of death in the US. Learn how neuroprotective effects of melatonin may help.

Think you might be gluten sensitive? Take the quiz: https://www.glutenfreesociety.org/gluten-sensitivity-intolerance-self-test/ Most people have heard of Leaky Gut, but it is rare to hear anyone talk about the concept of Leaky Brain Syndrome. Today I want to talk about one of the most debilitating diseases linked to a break down in the gastrointestinal barrier, but also potentially a break down in the blood brain barrier. Dementia. Unfortunately, many are unaware of the connection between gluten and dementia (Alzheimer’s). Part of this connection has to do with the role gluten plays in causing intestinal permeability (Leaky Gut). This process was discovered originally by Dr. Fasano. The part less talked about has to do with gluten’s impact on the microbiome (good bacteria in the gut). To connect with Dr. Osborne visit: On the web: https://drpeterosborne.com/ Facebook: https://www.facebook.com/DoctorPeterOsborne/ Pinterest: https://www.pinterest.com/docosborne/ Instagram: https://www.instagram.com/drosborne Twitter: https://twitter.com/glutenology *These statements have not been evaluated by the Food and Drug Administration. This video is not intended to diagnose, treat, cure or prevent any disease. It is strictly intended for educational purposes only. Additionally, this information is not intended to replace the advice of your physician. Dr. Peter Osborne is one of the most sought after alternative and nutritional experts in the world. A Diplomate with the American Clinical Board of Nutrition, a graduate of Texas Chiropractic College, and a doctor of pastoral science, Dr. Osborne is one of the world’s leading authorities on gluten, nutrition, and natural health. He is the founder GlutenFreeSociety.org, one of the world's largest informational sites on gluten sensitivity. In addition, he is the author of the best selling book, No Grain No Pain, published by Touchstone (Simon & Schuster). His work has been featured by PBS, Netflix, Amazon, Fox, and many other nationally recognized outlets. For more information, visit us at https://www.glutenfreesociety.org/ or call 281-903-7527

We want to do everything we can to keep our uric acid levels in the optimal range, typically below 5.5 mg/dl. And by far and away, the biggest contributor to the elevation of uric acid that we are seeing around the world seems to be the global increase in consumption of fructose sugar. That said, there are other contributors to the formation of uric acid, and one of them is alcohol. As it turns out, when we look at the metabolism of alcohol and recognize that it directly contributes to the formation of uric acid, we shouldn't be surprised that alcoholic beverages do in fact increase uric acid. To a significant degree it depends on what type of alcohol is consumed, and indeed there are some gender-specific findings as well that are important. This is important information that leverages the new and exciting research coming out from around the world on the threat posed by elevation of uric acid in terms of our health. In my new book, Drop Acid (https://www.drperlmutter.com/books/drop-acid/), I do a deep dive into the science of uric acid and provide a valuable game plan for getting uric acid levels under control. ___________________________ Instagram: https://www.instagram.com/davidperlmutter/ Website: https://www.drperlmutter.com/ Subscribe to our channel: https://www.youtube.com/channel/UCDRl_UAXxbHyOOjklnA0dxQ/?sub_confirmation=1

There is an ever-increasing body of evidence that clearly shows the incredible threat posed by dietary fructose in multiple areas of human health. A diet higher in fructose is associated with increased risk for weight gain and type 2 diabetes, and just considering these two processes alone, the stage becomes set for all kinds of other downstream maladies. We are now seeing robust data that relates fructose consumption to increased risk of brain degeneration and even compromised brain function. In this video, I explore one recent publication that was quite extensive and related fructose consumption in the form of beverages to a rapid increase in brain shrinkage as well as a significant decline in cognitive function. We then explore the mechanisms whereby this occurs including how fructose is metabolized into uric acid, compounding the threat to the brain. In my new book, Drop Acid (https://amzn.to/309RuqN), we go much deeper into the science that reveals how elevated uric acid, a product of fructose metabolism, poses such a significant threat to the brain. ___________________________ Instagram: https://www.instagram.com/davidperlmutter/ Website: https://www.drperlmutter.com/ Subscribe to our channel: https://www.youtube.com/channel/UCDRl_UAXxbHyOOjklnA0dxQ/?sub_confirmation=1

In our discussions in recent years about Alzheimer's disease, certainly one dietary recommendation seems to gain the spotlight and that is a ketogenic diet.

[et_pb_section bb_built=”1″][et_pb_row][et_pb_column type=”4_4″][et_pb_text _builder_version=”3.0.76″ background_layout=”light” border_style=”solid”] While death rates from cancer, heart disease and stroke continue to decrease, deaths related to Alzheimer’s Disease increased 38% from 2000-2010. This is an alarming statistic. Alzheimer’s also adversely affects more women than men, with 68% of people with Alzheimer’s being women. However, there is hope. Recent research has […]

Most everyone knows of a cancer survivor. But, by and large, when a person receives a diagnosis of Alzheimer's disease, it is often assumed that this is an indication of an almost certain outcome. Alzheimer's disease is not caused by a specific flaw. While energy deficiency, inflammation, infectious agents, beta amyloid, acetylcholine deficiency, trauma, toxins, metabolic issues, and genetics are all worthy of consideration, it is clearly myopic to consider that targeting one of these popular ideas is going to solve the problem. It doesn’t. Our guest today has taken a different approach. Rather than trying to find a unique drug or technique that can help the Alzheimer's population at large, this novel approach focuses on identifying how variations in multiple parameters can be targeted with the overall goal of improving brain functionality that is compromised in the developing Alzheimer's situation. This approach, a personalized medicine approach, directly challenges the notion of a one-size-fits-all mentality as it relates to treating medical problems. And to be sure, Dr. Bredesen is demonstrating incredible success not just in stabilizing Alzheimer's patients but actually in bringing about their improvement. This is revolutionary, and I urge you to pay close attention to his message today. ==== Dr. Bredesen received his undergraduate degree from Caltech and his medical degree from Duke. He served as Resident and Chief Resident in Neurology at UCSF, then was postdoctoral fellow in the laboratory of Nobel laureate Prof. Stanley Prusiner. He was a faculty member at UCLA from 1989-1994, then was recruited by the Burnham Institute to direct the Program on Aging. In 1998 he became the Founding President and CEO of the Buck Institute for Research on Aging, and Adjunct Professor at UCSF; then in 2013 he returned to UCLA as the Director of the Easton Center for Alzheimer’s Disease Research. The Bredesen Laboratory studies basic mechanisms underlying the neurodegenerative process, and the translation of this knowledge into effective therapeutics for Alzheimer’s disease and other neurodegenerative conditions, leading to the publication of over 220 research papers. He established the ADDN (Alzheimer’s Drug Development Network) with Dr. Varghese John in 2008, leading to the identification of new classes of therapeutics for Alzheimer’s disease. He and his group developed a new approach to the treatment of Alzheimer’s disease, and this approach led to the discovery of subtypes of Alzheimer’s disease, followed by the first description of reversal of symptoms in patients with MCI and Alzheimer’s disease, with the ReCODE (reversal of cognitive decline) protocol, published in 2014, 2016, and 2018. Dr. Bredesen is the author of the New York Times bestseller, The End of Alzheimer’s, and the newly released, The End of Alzheimer’s Program. His newest book, The First Survivors of Alzheimer’s, chronicles how this program has virtually rewritten the lives of so many, and reveals, from the patient’s perspective, what this has meant. Here’s a link to his latest research paper showing improvement in an astounding 80% of Alzheimer’s patients: https://www.drperlmutter.com/study/precision-medicine-approach-alzheimers-disease-successful-proof-concept-trial/ Twitter @DrDaleBredesen FB @drdalebredesen IG @drdalebredesen ___________________________ Instagram: https://www.instagram.com/davidperlmutter/ Website: https://www.drperlmutter.com/ Subscribe to our channel: https://www.youtube.com/channel/UCDRl_UAXxbHyOOjklnA0dxQ/?sub_confirmation=1

Dr. Dale Bredesen brings a personalized medicine approach to Alzheimer's treatment and he's seeing success and improvements in brain function.

Compared with a usual diet supplemented with low-fat healthy-eating guidelines, patients on the ketogenic diet improved in daily function and quality of...

In our discussions in recent years about Alzheimer's disease, certainly one dietary recommendation seems to gain the spotlight and that is a diet that helps produce ketones. To be fair, most of the support for a ketogenic diet thus far has been theoretical although early animal research has been supportive. Now, I'm excited to report that an actual interventional trial using the ketogenic diet in Alzheimer's patients has been completed and has demonstrated quite remarkable results. The study, performed by my friend Dr. Matthew Phillips in New Zealand, demonstrated significant improvement in a variety of parameters in Alzheimer's patients who were placed on a ketogenic diet in comparison to their standard diet. Here is the actual study: https://www.drperlmutter.com/study/randomized-crossover-trial-of-a-modified-ketogenic-diet-in-alzheimers-disease/ https://www.drperlmutter.com/ketogenic-diet-proves-effective-in-alzheimers-disease/ Many of you may remember Dr. Phillips as he appeared on the podcast in the past describing his results of using a ketogenic diet, successfully, in Parkinson's disease: https://www.drperlmutter.com/the-empowering-neurologist-with-dr-matthew-phillips/ Here's more information about him. ==== Matt is a full-time clinical and research neurologist at Waikato Hospital, Hamilton, New Zealand. His foremost passion is to explore the potential feasibility, safety, and efficacy of metabolic therapies, particularly fasting and ketogenic diets, in creating alternate metabolic states that may improve not only the symptoms, but also function and quality of life, for people with a variety of difficult disorders. ___________________________ Instagram: https://www.instagram.com/davidperlmutter/ Website: https://www.drperlmutter.com/ Subscribe to our channel: https://www.youtube.com/channel/UCDRl_UAXxbHyOOjklnA0dxQ/?sub_confirmation=1

Drs. Ayesha and Dean Sherzai are the authors of The 30-Day Alzheimer’s Solution. It is most user-friendly book dedicated to brain health.

During the last years, epigenetic processes have emerged as important factors for many neurodegenerative diseases, such as Alzheimer’s disease (AD). These complex diseases seem to have a heritable component; however, genome-wide association studies failed to identify the genetic loci involved in the etiology. So, how can these changes be transmitted from one generation to the next? Answering this question would allow us to understand how the environment can affect human populations for multiple generations and explain the high prevalence of neurodegenerative diseases, such as AD. This review pays particular attention to the relationship among epigenetics, cognition, and neurodegeneration across generations, deepening the understanding of the relevance of heritability in neurodegenerative diseases. We highlight some recent examples of EI induced by experiences, focusing on their contribution of processes in learning and memory to point out new targets for therapeutic interventions. Here, we first describe the prominent role of epigenetic factors in memory processing. Then, we briefly discuss aspects of EI. Additionally, we summarize evidence of how epigenetic marks inherited by experience and/or environmental stimuli contribute to cognitive status offspring since better knowledge of EI can provide clues in the appearance and development of age-related cognitive decline and AD.

In Alzheimer’s disease (AD), amyloid-β (Aβ) oligomers are considered key mediators of synaptic dysfunction and cognitive impairment. These unstable intermediate Aβ species can interfere with different cellular organelles, leading to neuronal cell death, through the formation of Ca2+-permeable membrane pores, impairment in the levels of acetylcholine neurotransmitters, increased insulin resistance, promotion of pro-inflammatory cascades, among others. Based on a series of evidences that indicate the key role of glycosaminoglycans (GAGs) in amyloid plaque formation, we evaluated the capacity of four monosaccharides, i.e., glucosamine (GlcN), N-acetyl glucosamine (GlcNAc), glucosamine-6-sulfate (GlcN6S), and glucosamine-6-phosphate (GlcN6P), to reduce the Aβ-mediated pathological hallmarks. The tested monosaccharides, in particular, GlcN6S and GlcN6P, were able to interact with Aβ aggregates, reducing neuronal cell death, Aβ-mediated damage to the cellular membrane, acetylcholinesterase activity, insulin resistance, and pro-inflammation levels.

Folder

Drugs being used to treat Alzheimer’s disease are actually associated with a more aggressive decline in cognitive function.